

Recommendations from York and Scarborough Medicines Commissioning Committee 21 January 2015

Drug name	Indication	Recommendation	Place in therapy	RAG status	Potential full year cost impact
Dabigatran etexilate (Pradaxa®)	Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	Approved	Recommended as an option in accordance with NICE TA 327	Green	Would represent a cost substitution where used in place of another NICE approved NOAC.
Brinzolamide & brimonidine combination eye drops (Simbrinza®)	Ocular hypertension	Not approved	Single separate eye drop preparations are available for use. Brinzolamide has recently patent expired therefore primary care costs expected to fall over coming months.	Black	Actual last 12 month spend £8.54
Dexamethasone intravitreal injection (Ozurdex®)	Uveitis	Approved (with restrictions)	To be used by the ophthalmology specialist in accordance with the treatment protocol.	Red	Nil
Fluticasone & azelastine combination nasal spray (Dymista®)	Allergic rhinitis	Not approved	The single separate nasal spray products are available where indicated.	Black	Actual last 12 month spend £2,080.48
Nebivolol tablets (All products)	Chronic heart failure	Not approved	Current position upheld – this treatment is not commissioned. Current formulary choices licensed for heart failure are bisoprolol or carvedilol.	Black	12 month spend approx. £128,000
Doxazosin MR tablets (All brands including Cardura XL®)	Hypertension and benign prostate hyperplasia	Not approved	Where doxazosin is clinically indicated, the standard plain tablets are the formulary choice.	Black	Actual last 12 month spend £29,916

Additional items:

Vale of York CCG medal ranking – erectile dysfunction approved by MCC December 2014

York and Scarborough Teaching hospital NHS Trust (items approved)

- Shared care guideline – melatonin for treatment of sleep disorders in children with visual problems and learning difficulties, cerebral palsy and autistic spectrum disorders (unlicensed indication).
- Thrombo-prophylaxis in adult out-patients (>16yrs) with non-surgical lower limb immobilisation – Communication to GPs.

Leeds and York Mental Health Partnership Trust

Donepezil, galantamine and rivastigmine have been reclassified as amber (no shared care guideline). This means that they are subject to specialist initiation and stabilisation but the medication requires no specific monitoring thereafter and prescribing responsibility may be transferred to primary care.